Consultation hotline:
  • January 2015
    Series A funding invested by Legend Capital & Legend Star (¥25 M)
  • September 2015
    Moved in a new research and development Lab with 800m2 SPF animal facility and a 400m2 cell culture room. Located in PKU Healthcare Industrial Park.
  • February 2017
    Series B funding lead by Panlin Capital (¥50 M)
  • April 2017
    Sponsored Clinical Trial (investigator-initiated trial, IIT) “Rapid screening for individualized chemotherapy optimization of colorectal cancer with a novel conditional reprogramming technology-based functional diagnostic assay.”
  • August 2017
    Launched new i-CR® technology platform Lauched RUO products for primary tumor cell: storage, isolation, in vitro culture and drug testing.
  • January 2018
    Cothera Bioscience, Inc.Angel Investment ($5.5M).
  • May 2019
    Restructured Cothera-Percans company builded an international team and an advanced basic research platform.
  • November 2019
    License in PC-002
  • December 2020
    Cothera Bioscience completed the series-B financing, and obtained USD 30 million of investment
  • June 2021
    Cothera Receives Authorization from the FDA to Conduct a Phase 2 Clinical Trial to Test Its Targeted MYC Mutation Inhibitor PC-002 for the Treatment of High-Grade B-cell Lymphoma
  • September 2021
    License in CDK inhibitor Zotiraciclib
  • September 2021
    Cothera Receives Authorization from the FDA to Conduct a Phase 2 Clinical Trial to Test PC-002 for the Treatment of Neuroendocrine Prostate Cancer (NEPC)
  • March 2022
    The NMPA has approved a Phase II clinical trial of PC-002 for high-grade B-cell lymphoma
Copyright 2015 Beijing zhikangbo Medical Oncology Research Co., Ltd 京公网安备 11011402013345号